Novotech, a global full-service clinical Contract Research Organization (CRO), has released its latest disease report, Hepatitis B - Global Clinical Trial Landscape (2025). The report offers a comprehensive analysis of global trends, challenges, and emerging opportunities in the Hepatitis B clinical research ecosystem.

Leveraging Novotech’s extensive experience, the report provides valuable insights for biotech companies, healthcare professionals, and stakeholders involved in Hepatitis B research. Key highlights include:

Epidemiology Overview: Insights into the global burden of Hepatitis B, focusing on high-prevalence regions such as Asia-Pacific and Africa.

Clinical Trial Landscape: An analysis of over 100 industry-sponsored trials globally, with Asia-Pacific leading in trial density and innovation. Novotech has managed 90 trials in the region, with Australia hosting 79 and contributions from Hong Kong, Taiwan, New Zealand, South Korea, and Thailand.

Drug Pipeline Innovations: An exploration of advanced therapeutic modalities, including RNA-based therapies, antisense oligonucleotides, monoclonal antibodies, and therapeutic vaccines.

Biomarkers and Clinical Endpoints: A guide to emerging biomarkers like HBV RNA and HBcrAg, and their role in optimizing clinical outcomes and trial designs.

The report also notes a 31.95% CAGR in Hepatitis B trials from 2020 to 2024, driven by advancements in small molecules, siRNA therapies, and therapeutic vaccines. Novotech is a global leader in Hepatitis B research, having supported 90 trials, initiated over 340 sites, and enrolled more than 5,000 participants across all trial phases, including 65 Phase I and 25 Phase II studies.

The Hepatitis B - Global Clinical Trial Landscape (2025) report is now available for download, offering actionable insights to guide clinical development strategies and optimize trial execution.

Source: https://novotech-cro.com/news/novotech-releases-hepatitis-b-global-clinical-trial-landscape-report-2025